SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending as investors react to a government-backed funding initiative, fueling intense debate between bulls anticipating a potential short squeeze and skeptics raising concerns over extreme valuations and dilution. The stock's volatile price action has triggered widespread community discussion regarding the sustainability of the rally and the impact of the newly announced capital injection on future growth.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing heightened investor attention following a positive fireside chat at the CIBC Technology & Innovation Conference, where leadership highlighted profitable growth and a strong backlog in the QNX and secure communications divisions. The community is actively discussing the company's evolving role in the physical AI and robotics sectors, with many investors debating the long-term potential of the QNX operating system as a foundational element in high-performance edge computing.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is rallying as investors react to a government initiative providing federal funding and equity stakes to support the development of quantum technology. The community is heavily focused on the stock's high short interest and the potential for a significant squeeze, while debates persist regarding the firm's long-term commercial scalability and the impact of the newly announced government support.

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company was founded on October 7, 2004 and is headquartered in Tampa, FL.

Akari Therapeutics Plc - ADR

Akari Therapeutics

Akari Therapeutics is surging following positive preclinical data for its lead ADC program, AKTX-101, which demonstrated synergistic potential in treating KRAS-mutated pancreatic cancer. The community is actively discussing the stock's significant momentum and low-float volatility, with traders closely monitoring volume sustainability and key resistance levels as the company advances its oncology pipeline.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending ahead of its quarterly earnings release as investors weigh aggressive expansion into hotel bookings and delivery against competitive concerns in the autonomous vehicle sector. The community is actively debating the company's valuation and the potential for long-term growth versus persistent short-term price stagnation.

Hyliion Holdings Corp. engages in the development of sustainable electricity-producing technology. It focuses on providing modular power plant technology that can operate on various fuel sources through the KARNO power module. The company was founded by Thomas J. Healy in 2015 and is headquartered in Cedar Park, TX.

Hyliion Holdings Corporation - Ordinary Shares - Class A

Hyliion Holdings Corp

Hyliion Holdings Corp is seeing a massive surge in volume and investor interest as community members highlight its KARNO power module as a critical solution for AI data centers requiring native 800-volt DC efficiency. Sentiment is buoyed by speculative excitement regarding military and space-sector partnerships, though a vocal contingent of traders is actively warning of potential volatility and dilution risks following the rapid rally.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is seeing intense community debate driven by anticipation of upcoming earnings and potential reactions to shareholder meeting votes, particularly regarding authorization for reverse splits. Investors are closely monitoring prescription growth and GPO agreement impacts on commercial reach, while conflicting narratives between bullish expectations for the Tonmya launch and bearish concerns over cash burn and dilution continue to fuel heavy social media engagement.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending due to a major sector-wide catalyst involving the U.S. government's announcement of a multi-billion dollar quantum computing initiative. The community is actively debating the implications of IonQ's exclusion from this specific funding round, while long-term bulls argue its independent financial strength and strategic acquisitions solidify its position as a sector leader.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Kennedy Space Center, FL.

Starfighters Space Inc

Starfighters Space is trending due to a private placement investment aimed at accelerating its STARLAUNCH platform, drawing intense community debate over its potential as a 'space sector' play. Investors remain deeply divided, with some betting on institutional accumulation and the upcoming SpaceX IPO as catalysts, while others warn of significant cash burn, potential dilution, and concerns regarding corporate governance and executive turnover.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is experiencing significant volatility and intense debate among investors as they navigate a strategic pivot toward AI data center infrastructure. The community remains deeply divided, with some highlighting the company's high-efficiency GaN technology and key industry partnerships as catalysts for long-term growth, while others express skepticism regarding the company's current revenue levels, path to profitability, and high valuation relative to its peers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NRx Pharmaceuticals, Inc. (NRXP) Reports Q1 Loss, Lags Revenue Estimates

NRx Pharmaceuticals (NRXP) delivered earnings and revenue surprises of +20.00% and -91.28%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

NRx Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

NRx Pharma (NRXP) set to release Q1 earnings on May 18. Analysts expect $19.43 million in revenue, with a loss of 11 cents per share. FDA clearance received for clinical trial.read more...

D. Boral Capital Reaffirms Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

D. Boral Capital restated a 'buy' rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Sees Large Growth in Short Interest

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) was the recipient of a significant growth in short interest during the month of April. As of April 15th, there was short interest totaling...

Equities Analysts Offer Predictions for NRXP Q1 Earnings

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Free Report) - Research analysts at HC Wainwright issued their Q1 2027 earnings estimates for NRx Pharmaceuticals in a note issued to investors on Monday...

NRx Pharmaceuticals (NASDAQ:NRXP) Earns "Buy" Rating from HC Wainwright

HC Wainwright reiterated a "buy" rating and set a $45.00 price target on shares of NRx Pharmaceuticals in a report on Monday...

NRx Pharmaceuticals (NASDAQ:NRXP) Price Target Raised to $49.00 at Ascendiant Capital Markets

Ascendiant Capital Markets lifted their price target on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the stock a "buy" rating in a research note on Monday...

NRx Pharmaceuticals' (NRXP) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated a "buy" rating and set a $34.00 target price on shares of NRx Pharmaceuticals in a research note on Monday...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Rating of "Moderate Buy" from Analysts

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) has been given an average rating of "Moderate Buy" by the six brokerages that are currently covering the stock, MarketBeat reports. One...

NRx Pharmaceuticals' (NRXP) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated a "buy" rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research report on Tuesday...

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded by Jonathan C. Javitt on September 18, 2017 and is headquartered in Wilmington, DE.

Current Price	$3.32
Prev Close	$3.06
Open	$3.09
Dividend Yield	0.00%
50-Day Moving Average	$2.57
Beta	1.20
Avg. Volume	1.06M
PE Ratio	-2.39

52-Week High	$3.84
52-Week Low	$1.62
Market Capitalization	$110.86M
EPS (Annual)	-$1.34
Price to Book	-7.41
Revenue Per Employee	N/A

NRXP
NRX Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest NRXP News

NRXPNRX Pharmaceuticals Inc